Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2021

01-12-2021 | Obesity | Research

Clinical and demographic features among patients with type 1 diabetes mellitus in Henan, China

Authors: Liguo Yang, Guangxing Yang, Xialian Li

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

The hallmark of type 1 diabetes (T1D) is an absolute lack of insulin. However, many studies showed a tendency to heterogeneity in TID. We aimed to investigate the demographic and clinical characteristics in T1D and the differences in young-onset and adult-onset patients.

Methods

This retrospective study was conducted among 1943 patients with clinically diagnosed T1D. Medical records on patients’ demographics, anthropometric measurements, and clinical manifestation were collected. According to the age at onset, the newly diagnosed patients were divided into the young-onset group (< 18 years, 234 patients, mean age 11 years) and adult-onset group (≥ 18 years, 219 patients, mean age 27 years). Pancreatic β-cell function was assessed by fasting C-peptide (FCP) and 2-h C-peptide (2-h CP).

Results

The median age of patients at disease onset was 22 years. The median duration of patients was 3 years. The overall median glycated hemoglobin (HbA1c) value was 10.3 % [89(mmol/mol)]. The prevalence of diabetic retinopathy was 25.1 %. The overall rate of DKA at onset in the new-onset patients was 59.6 %. The frequency of overall dyslipidemia was 37.8 %. The most frequent dyslipidemia was low high-density lipoprotein-cholesterol (HDL) (29 %). The proportion of patients with anti-glutamic acid decarboxylase (GADA), insulin antibody (IAA) and islet cell antibody (ICA) were 28.1 %, 6.4 % and 21.6 %, respectively. The mean HbA1c showed a downward trend with age. Increasing or decreasing trends of overweight and obesity in this population during the period 2012 to 2018 was not found.
Compared with young-onset T1D, adult-onset patients comprised better islet function (FCP: 0.4 vs. 0.3 ng/ml, P < 0.001; 2-h CP: 0.9 vs. 0.7 ng/ml P < 0.001, respectively) and glycemic control [12.9 % (117mmol/mol) vs. 11.7 % (104mmol/mol), P < 0.001], higher prevalence of diabetes condition in the male gender (64.4 % vs. 51.3 %, P = 0.006), higher proportion of obesity or overweight (24.6 % vs. 9.5 %, P = 0.002), higher frequency of GADA (33.7 % vs. 23.3 %, P = 0.025), and lower frequency of diabetic ketoacidosis at disease onset (64.5 % vs. 43.5 %, P < 0.001).

Conclusions

This population was characterized by poor overall blood glucose control, high prevalence of DKA, dyslipidemia and diabetic retinopathy, and low prevalence of islet-related antibodies, and overweight or obesity. Adult-onset patients with T1D were not uncommon and had better clinical manifestations than young-onset patients. Any findings related to body mass index (BMI) and autoantibodies should be considered strictly exploratory due to excessive missing data.
Literature
1.
Eisenbarth GS: Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986, 314(21):1360–1368.PubMedCrossRef
2.
Writing Group for the SfDiYSG, Dabelea D, Bell RA, D’Agostino RB, Jr., Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S et al: Incidence of diabetes in youth in the United States. JAMA 2007, 297(24):2716–2724.CrossRef
3.
Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G, Group ES: Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373(9680):2027–2033.PubMedCrossRef
4.
Harjutsalo V, Sjoberg L, Tuomilehto J: Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008, 371(9626):1777–1782.PubMedCrossRef
5.
Group DP: Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999. Diabet Med 2006, 23(8):857–866.CrossRef
6.
Parviainen A, But A, Siljander H, Knip M, Finnish Pediatric Diabetes R: Decreased Incidence of Type 1 Diabetes in Young Finnish Children. Diabetes Care 2020, 43(12):2953–2958.PubMedCrossRef
7.
Gong C, Meng X, Saenger P, Wu D, Cao B, Wu D, Wei L: Trends in the incidence of childhood type 1 diabetes mellitus in Beijing based on hospitalization data from 1995 to 2010. Horm Res Paediatr 2013, 80(5):328–334.PubMedCrossRef
8.
Zhao Z, Sun C, Wang C, Li P, Wang W, Ye J, Gu X, Wang X, Shen S, Zhi D et al: Rapidly rising incidence of childhood type 1 diabetes in Chinese population: epidemiology in Shanghai during 1997–2011. Acta Diabetol 2014, 51(6):947–953.PubMedCrossRef
9.
Fu JF, Liang L, Gong CX, Xiong F, Luo FH, Liu GL, Li P, Liu L, Xin Y, Yao H et al: Status and trends of diabetes in Chinese children: analysis of data from 14 medical centers. World J Pediatr 2013, 9(2):127–134.PubMedCrossRef
10.
Hermann R, Knip M, Veijola R, Simell O, Laine AP, Akerblom HK, Groop PH, Forsblom C, Pettersson-Fernholm K, Ilonen J et al: Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes–indication of an increased environmental pressure? Diabetologia 2003, 46(3):420–425.PubMedCrossRef
11.
Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith GJ, Rewers M, Dabelea D: Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes. Diabetes Care 2008, 31(7):1392–1396.PubMedPubMedCentralCrossRef
12.
American Diabetes A: 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020, 43(Suppl 1):S14-S31.
13.
Chiang JL, Kirkman MS, Laffel LM, Peters AL, Type 1 Diabetes Sourcebook A: Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014, 37(7):2034–2054.PubMedPubMedCentralCrossRef
14.
Weng J, Zhou Z, Guo L, Zhu D, Ji L, Luo X, Mu Y, Jia W, Group TDCS: Incidence of type 1 diabetes in China, 2010-13: population based study. BMJ 2018, 360:j5295.PubMedPubMedCentralCrossRef
15.
Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C et al: Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care 2020, 43(1):5–12.PubMedCrossRef
16.
Tosur M, Redondo MJ: Heterogeneity of Type 1 Diabetes: The Effect of Ethnicity. Curr Diabetes Rev 2018, 14(3):266–272.PubMedCrossRef
17.
Ilonen J, Lempainen J, Veijola R: The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol 2019, 15(11):635–650.PubMedCrossRef
18.
Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J: Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000, 23(10):1516–1526.PubMedCrossRef
19.
Park Y, Eisenbarth GS: Genetic susceptibility factors of Type 1 diabetes in Asians. Diabetes Metab Res Rev 2001, 17(1):2–11.PubMedCrossRef
20.
Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besancon S, Bommer C, Esteghamati A, Ogurtsova K, Zhang P et al: Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2020, 162:108072.
21.
Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539–553.PubMedCrossRef
22.
Hother-Nielsen O, Faber O, Sorensen NS, Beck-Nielsen H: Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 1988, 11(7):531–537.PubMedCrossRef
23.
Yang D, Deng H, Luo G, Wu G, Lin S, Yuan L, Xv M, Li S, Zhang X, Wu J et al: Demographic and clinical characteristics of patients with type 1 diabetes mellitus: A multicenter registry study in Guangdong, China. J Diabetes 2016, 8(6):847–853.PubMedCrossRef
24.
Huo L, Ji L, Deng W, Shaw JE, Zhang P, Zhao F, McGuire HC, Kissimova-Skarbek K, Whiting D: Age distribution and metabolic disorders in people with Type 1 diabetes in Beijing and Shantou, China: a cross-sectional study. Diabet Med 2018, 35(6):721–728.PubMedCrossRef
25.
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E et al: State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther 2019, 21(2):66–72.PubMedPubMedCentralCrossRef
26.
Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977–986.CrossRef
27.
Aiello LP, Group DER: Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014, 37(1):17–23.PubMedCrossRef
28.
Samuelsson U, Steineck I, Gubbjornsdottir S: A high mean-HbA1c value 3–15 months after diagnosis of type 1 diabetes in childhood is related to metabolic control, macroalbuminuria, and retinopathy in early adulthood–a pilot study using two nation-wide population based quality registries. Pediatr Diabetes 2014, 15(3):229–235.PubMedCrossRef
29.
Carlsen S, Skrivarhaug T, Thue G, Cooper JG, Goransson L, Lovaas K, Sandberg S: Glycemic control and complications in patients with type 1 diabetes - a registry-based longitudinal study of adolescents and young adults. Pediatr Diabetes 2017, 18(3):188–195.PubMedCrossRef
30.
Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA, Network TDEC: The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012, 97(12):4383–4389.PubMedCrossRef
31.
Hammes HP, Kerner W, Hofer S, Kordonouri O, Raile K, Holl RW, Group DP-WS: Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. Diabetologia 2011, 54(8):1977–1984.PubMedCrossRef
32.
Cho YH, Craig ME, Hing S, Gallego PH, Poon M, Chan A, Donaghue KC: Microvascular complications assessment in adolescents with 2- to 5-yr duration of type 1 diabetes from 1990 to 2006. Pediatr Diabetes 2011, 12(8):682–689.
33.
Sochett E, Daneman D: Early diabetes-related complications in children and adolescents with type 1 diabetes. Implications for screening and intervention. Endocrinol Metab Clin North Am 1999, 28(4):865–882.PubMedCrossRef
34.
Pinhas-Hamiel O, Levek-Motola N, Kaidar K, Boyko V, Tisch E, Mazor-Aronovitch K, Graf-Barel C, Landau Z, Lerner-Geva L, Frumkin Ben-David R: Prevalence of overweight, obesity and metabolic syndrome components in children, adolescents and young adults with type 1 diabetes mellitus. Diabetes Metab Res Rev 2015, 31(1):76–84.PubMedCrossRef
35.
Maffeis C, Birkebaek NH, Konstantinova M, Schwandt A, Vazeou A, Casteels K, Jali S, Limbert C, Pundziute-Lycka A, Toth-Heyn P et al: Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: Data from the international SWEET registry. Pediatr Diabetes 2018, 19(7):1211–1220.PubMedCrossRef
36.
Kaminski BM, Klingensmith GJ, Beck RW, Tamborlane WV, Lee J, Hassan K, Schatz D, Kollman C, Redondo MJ, Pediatric Diabetes C: Body mass index at the time of diagnosis of autoimmune type 1 diabetes in children. J Pediatr 2013, 162(4):736–740 e731.PubMedCrossRef
37.
Fellinger P, Fuchs D, Wolf P, Heinze G, Luger A, Krebs M, Winhofer Y: Overweight and obesity in type 1 diabetes equal those of the general population. Wien Klin Wochenschr 2019, 131(3–4):55–60.PubMedPubMedCentralCrossRef
38.
Cui Z, Huxley R, Wu Y, Dibley MJ: Temporal trends in overweight and obesity of children and adolescents from nine Provinces in China from 1991–2006. Int J Pediatr Obes 2010, 5(5):365–374.PubMedCrossRef
39.
Schwab KO, Doerfer J, Hecker W, Grulich-Henn J, Wiemann D, Kordonouri O, Beyer P, Holl RW, Diabetology DPVIotGWGfP: Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006, 29(2):218–225.PubMedCrossRef
40.
Kim SH, Jung IA, Jeon YJ, Cho WK, Cho KS, Park SH, Jung MH, Suh BK: Serum lipid profiles and glycemic control in adolescents and young adults with type 1 diabetes mellitus. Ann Pediatr Endocrinol Metab 2014, 19(4):191–196.PubMedPubMedCentralCrossRef
41.
Zabeen B, Balsa AM, Islam N, Parveen M, Nahar J, Azad K: Lipid Profile in Relation to Glycemic Control in Type 1 Diabetes Children and Adolescents in Bangladesh. Indian J Endocrinol Metab 2018, 22(1):89–92.PubMedPubMedCentralCrossRef
42.
Homma TK, Endo CM, Saruhashi T, Mori AP, Noronha RM, Monte O, Calliari LE: Dyslipidemia in young patients with type 1 diabetes mellitus. Arch Endocrinol Metab 2015, 59(3):215–219.PubMedCrossRef
43.
Trisorus C, Aroonparkmongkol S, Kongmanas HB, Sahakitrungruang T: Prevalence of islet autoantibodies in Thai juvenile-onset type 1 diabetes. Pediatr Int 2018, 60(11):1002–1007.PubMedCrossRef
44.
Alyafei F, Soliman A, Alkhalaf F, Sabt A, De Sanctis V, Elsayed N, Waseef R: Prevalence of beta-cell antibodies and associated autoimmune diseases in children and adolescents with type 1 diabetes (T1DM) versus type 2 diabetes (T2DM) in Qatar. Acta Biomed 2018, 89(S5):32–39.PubMedPubMedCentral
45.
Al-Abady HL, Mahdi NK, Al-Naama LM, Mahdi JK: The prevalence of autoantibodies among relatives for type 1 and 2 diabetic patients. J Pak Med Assoc 2016, 66(9):1064–1067.PubMed
46.
Chao C, Huang G, Li X, Yang L, Lin J, Jin P, Luo SM, Zhang YY, Pan LL, Zhou ZG: Change of glutamic acid decarboxylase antibody and protein tyrosine phosphatase antibody in Chinese patients with acute-onset type 1 diabetes mellitus. Chin Med J (Engl) 2013, 126(21):4006–4012.
47.
Kupila A, Keskinen P, Simell T, Erkkila S, Arvilommi P, Korhonen S, Kimpimaki T, Sjoroos M, Ronkainen M, Ilonen J et al: Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes 2002, 51(3):646–651.PubMedCrossRef
48.
Lee YS, Ng WY, Thai AC, Lui KF, Loke KY: Prevalence of ICA and GAD antibodies at initial presentation of type 1 diabetes mellitus in Singapore children. J Pediatr Endocrinol Metab 2001, 14(6):767–772.PubMedCrossRef
49.
Andersson C, Larsson K, Vaziri-Sani F, Lynch K, Carlsson A, Cedervall E, Jonsson B, Neiderud J, Mansson M, Nilsson A et al: The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 2011, 44(5):394–405.PubMedCrossRef
50.
Steffes MW, Sibley S, Jackson M, Thomas W: Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26(3):832–836.PubMedCrossRef
51.
Picardi A, Visalli N, Lauria A, Suraci C, Buzzetti R, Merola MK, Manfrini S, Guglielmi C, Gentilucci UV, Pitocco D et al: Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. Horm Metab Res 2006, 38(10):668–672.PubMedCrossRef
52.
Bruno G, Cerutti F, Merletti F, Cavallo-Perin P, Gandolfo E, Rivetti M, Runzo C, Pinach S, Pagano G, Piedmont Study Group for Diabetes E: Residual beta-cell function and male/female ratio are higher in incident young adults than in children: the registry of type 1 diabetes of the province of Turin, Italy, 1984–2000. Diabetes Care 2005, 28(2):312–317.PubMedCrossRef
53.
Speigelman M, Marks HH: Age and sex variations in the prevalence and onset of diabetes mellitus. Am J Public Health Nations Health 1946, 36:26–33.PubMedCrossRef
54.
Vandewalle CL, Falorni A, Svanholm S, Lernmark A, Pipeleers DG, Gorus FK: High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J Clin Endocrinol Metab 1995, 80(3):846–851.PubMed
55.
Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, Salmela PI, Knip M: Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000, 23(9):1326–1332.PubMedCrossRef
Metadata
Title
Clinical and demographic features among patients with type 1 diabetes mellitus in Henan, China
Authors
Liguo Yang
Guangxing Yang
Xialian Li
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00799-2

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue

Research article

Increasing adiposity and the presence of cardiometabolic morbidity is associated with increased Covid-19-related mortality: results from the UK Biobank

Research

Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer

Review

Uric acid‐induced pancreatic β-cell dysfunction

Research

Developing a research database of primary aldosteronism: rationale and baseline characteristics

Research article

Correlation between PCT, 25(OH)D, PTX-3, AMS levels and the severity of diabetic ketoacidosis complicated by pancreatitis

Research

The relationship between changes in serum myostatin and adiponectin levels in patients with obesity undergoing a weight loss program
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits